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Vitiligo patients possess high frequencies of circulating
CD8þ T lymphocytes speci¢c for the melanocyte dif-
ferentiation antigen Melan-A/MART-1. These self-spe-
ci¢c T cells exhibit intact functional properties and
their T cell receptors are selected for a narrow range of
high a⁄nities of antigen recognition, suggesting their
important role in the pathogenesis of vitiligo. In order
to understand the molecular base for this unexpected,
optimal T cell receptor recognition of a self-antigen, a
tetramer-guided ex vivo analysis of the T cell receptor
repertoire speci¢c for the Melan-A antigen in a patient
a¡ected by vitiligo is reported. All T cell receptors se-
quenced corresponded to di¡erent clonotypes, exclud-
ing extensive clonal expansions and revealing a large
repertoire of circulating Melan-A-speci¢c T lympho-
cytes. A certain degree of Tcell receptor structural con-
servation was noticed, however, as a single AV segment
contributed to the a chain rearrangement in 100% of
clones and a conserved amino acid sequence was found
in the b chain complementarity determining region 3 of
various high a⁄nity cells.We suggest that the conserved
a chain confers self-antigen recognition, necessary for
intrathymic selection and peripheral homeostasis, to
many synonymous Tcell receptors, whereas the b chain
¢ne tunes theTcell receptor a⁄nity of the speci¢c cells.
In addition, we demonstrate that many high avidity T
cell clones from this patient were capable of speci¢cally
lysing normal, HLA-matched melanocytes. These auto-
reactive clones persisted for more than 3 y in the pa-
tient’s peripheral blood. These data, together with the
skin-homing potential of the clones, directly point to
the in vivo pathogenic role of melanocyte-speci¢c
cytotoxic T lymphocytes in vitiligo. Key words: cytotoxic
T lymphocytes/human/Melan-A/MART-1/T cell receptor/
vitiligo. J Invest Dermatol 121:308 ^314, 2003
V
itiligo is a skin disease a¡ecting approximately 1%
of the general population and is characterized by
the presence of depigmented macules and patches
as a consequence of local melanocyte loss. Despite
the fact that its etiology is not fully understood, vi-
tiligo is believed to be due to an autoimmune-mediated destruc-
tion of epidermal melanocytes. Although melanocyte-speci¢c
autoantibodies have been described in vitiligo patients, their
pathogenic role remains uncertain (Naughton et al, 1983; Betterle
et al, 1984; Song et al, 1994; Cui and Bystryn, 1995; Kemp et al,
1997; Merimsky et al, 1998; Okamoto et al, 1998). The patchy dis-
tribution of cutaneous depigmentation and the most frequent
symmetrical distribution of lesions support the hypothesis that
autoimmune melanocyte damage is induced by clones of lym-
phocytes with a⁄nities for speci¢c areas of skin (al Badri et al,
1993). Evidence for the involvement of cellular immunity in the
pathogenesis of vitiligo is further provided by cases of in£amma-
tory vitiligo (Le Poole et al, 1996) and by the frequent observation
of skin-homing melanocyte-speci¢c cytotoxic T lymphocytes
(CTL) in the peripheral blood of vitiligo patients (Ogg et al,
1998; Lang et al, 2001; Palermo et al, 2001).
The presence in the periphery of high numbers of CTL speci-
¢c for self-antigens is not completely understood. The ability to
discriminate self from nonself is a crucial property of the im-
mune system. Self-peptides play a pivotal role in the shaping of
theTcell receptor (TCR) repertoire. Selection of theTCR reper-
toire during thymic development begins with positive selection
of Tcells expressing receptors with low a⁄nity for self major his-
tocompatibility complex (MHC) and negative selection of the
high a⁄nity cells (Kreuwel and Sherman, 2001). The persistence
in the peripheral repertoire requires homeostatic division, and
this too relies on repeated TCRMHC low a⁄nity interactions
and recognition of self-epitopes (Kreuwel and Sherman, 2001). As
a consequence, only antigen-speci¢c T cells characterized by a
low avidity phenotype for self-antigens are expected to remain
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una¡ected by intrathymic and/or extrathymic deletion (Liu et al,
1995; Morgan et al, 1998; Lee et al, 1999;Wang et al, 1999).
In this study, we focused on the analysis of the TCR repertoire
that is speci¢c for the HLA-A2-restricted immunodominant epi-
tope derived from the melanocyte di¡erentiation antigen Melan-
A/MART-1 (Melan-A hereafter). Melan-A is a 118 amino acid
membrane protein of unknown function, expressed by normal
melanocytes, by most fresh melanoma samples, and by about
60% of melanoma cell lines (Valmori et al, 1998; Skipper et al,
1999). The immunodominance of Melan-A antigen, in associa-
tion with HLA-A2, has received particular attention from the im-
munotherapeutic standpoint, as this HLA allele is predominant in
the North American Caucasian population, and Melan-A reactiv-
ity is frequent in tumor-in¢ltrating lymphocytes from HLA-A2
melanoma patients. A speci¢c allele-ligand combination capable
of unique interaction with the potential of the mature human
TCR repertoire appears to be the major contributor to this im-
munodominance (Bettinotti et al, 1998). Vitiligo patients have
been demonstrated to possess high frequencies of Melan-A-speci-
¢c circulating CTL (Lang et al, 2001; Palermo et al, 2001). These
autoreactive T cells exhibited intact functional properties asso-
ciated with antimelanocyte activity, as indicated by their consis-
tent ability to undergo in vitro expansion and to lyze HLA-
matched melanoma cell lines. Their TCRwere selected for a nar-
row range of high avidities of antigen recognition. In order to
understand the molecular base for this unexpected, optimal
TCR recognition of a self-antigen in vitiligo, we performed a
tetramer-guided ex vivo analysis of the TCR repertoire speci¢c
for Melan-A in one patient.
MATERIALS AND METHODS
Patient PSA is a female HLA-An0201 homozygote patient a¡ected by
nonfamilial, nonsegmental, patchy vitiligo di¡use on the face, arms,
hands, axillae, and legs. The disease a¡ects 60% of the patient’s body
surface and it has been stable for more than 10 y. The patient does not
su¡er from any other related autoimmune disease and remained free of
therapy during the follow-up period relative to this study (3 y). All
investigations were performed after approval by the local institutional
review board and according to the Declaration of Helsinki principles.
Tcell lines For the generation of peptide-speci¢c T cell lines, peripheral
blood mononuclear cells (PBMC) were monocyte depleted by exclusion of
plastic adherent cells. PBMC 105 per well were cultured in complete RPMI
medium in the presence of 105 peptide-pulsed HLA-A2þ TAP-de¢cient T2
cells (Ljunggren et al, 1990), using 1^2 mg per ml of Melan-A A27L peptide.
Low dose (25 U per ml) interleukin-2 was added on day 5. Cells were
stimulated at 3 wk intervals.
Fluorescence cell sorting and Tcell cloning PBMC were sorted into
de¢ned populations using a FACSVantage SE and data were analyzed by
CellQuest software (Becton-Dickinson, Mountain View, CA). Sorting
conditions are described by Mantovani et al (2002). Immediate re-analysis
of the sorted populations revealed more than 98% puri¢cation e⁄ciency.
For the cloning experiments, either sorted cells or tetramerþ enriched T
cell lines were plated at 0.3 cells per well in complete RPMI medium in
the presence of irradiated PBMC (5105 cells per ml), 2 mg per ml
phytohemagglutinin, and 250 U per ml recombinant interleukin-2.
Peptides and tetramers The following peptides were purchased from
Primm (Milan, Italy): Melan-A26^35 (EAAGIGILTV), Melan-A A27L (an
analog of the Melan-A26^35 epitope carrying a substitution of Ala for Leu
at position 2 from the NH2 terminus, ELAGIGILTV) (Valmori et al, 1998),
and MAGE-3271^279 (FLWGPRALV). MHC/peptide tetramer built around
the Melan-A A27L peptide was purchased from Beckman-Coulter (iTAg
MHC tetramers, San Diego, CA).
Antibodies and £ow cytometry PBMC were stained with tetramer-
PE (0.5 mg per 106 cells) for 15 min at 371C; after two washes, indirect
double-staining was performed on ice using antihuman CD8 monoclonal
antibody (OKT8, IgG2a) and £uorescein isothiocyanate (FITC) labeled
goat antimouse IgG2a (Southern Biotechnology Associates, Birmingham,
AL) as a second antibody. Triple stainings with tetramer-PE, anti-
CD45RA-CYC (Becton-Dickinson), and either anti-CD45RO-FITC
(Caltag Laboratories, Burlingame, CA) or puri¢ed anti-CD28 (mouse
IgG1; Pharmingen, San Diego, CA) were performed to assess the na|«ve/
e¡ector/memory phenotype of tetramerþ cells. FITC-labeled anti
cutaneous lymphocyte antigen (anti-CLA) monoclonal antibody HECA-
452 (rat IgM; Pharmingen) was used to stain CTL clones for 30 min on
ice. Cells were analyzed on a FACSCalibur machine (Becton-Dickinson).
Cytotoxicity assays To determine avidity in antigen recognition,
titration curves over a wide range of Melan-A A27L and Melan-A26^35
peptide concentrations (3102 nM to 5103 nM) were generated and
avidity of the di¡erent clones was determined as the concentration of
peptide required to obtain half maximal lysis ([nM]50%) of target cells in
a standard 4 h chromium release assay, at a low e¡ector:target cell (E:T)
ratio (5:1). Cytotoxicity was performed as described elsewhere (Palermo
et al, 2001).
T cell clones were also tested for speci¢c lysis against HLA-A2þ normal
melanocyte cell lines (kindly provided by Meenhard Herlyn, Wistar
Institute, Philadelphia, PA, and derived from newborn foreskins) in a 5 h
chromium release assay. An HLA-A2^ normal melanocyte cell line was
used as a negative control. 103 target cells per well were mixed with
appropriate amounts of e¡ector cells to give ¢nal E:T ratios ranging
between 3:1 and 80:1.
For the redirected lysis assay, 20106 target cells were labeled with 370
mCi 51Cr for 2 h at 371C. Erythrocytes were pulsed with B9.12.13 antibody,
a bimodal antibody able to bind CD3 and costimulatory molecules
to trigger a not-peptide mediated lysis (kindly provided by Dr A.
Lanzavecchia, IRB, Bellinzona, Switzerland), for 40 min at room
temperature. 3104 target cells per well were mixed with appropriate
amounts of e¡ector cells to give ¢nal E:T ratios ranging between 0.1:1 and
2:1 for 5 h. Erythrocytes not pulsed with the antibody were used as
negative controls at the E:T ratio of 2:1.
TCR downregulation assay T2 target cells were pulsed for 1.5 h with
various concentrations of Melan-A26-35 or Melan-A A27L peptides in
serum-free medium (X-VIVO 15; BioWhittaker, Walkersville, MD) at
371C, washed four times, and then added to e¡ector cells to give an E:T
ratio of 1:5. After 1.5^3 h at 371C, TCR internalization was measured by
£ow cytometry using an anti-TCR antibody (Immune Source, Los Altos,
CA). Data were analyzed as described by Mantovani et al (2002).
Ampli¢cation and sequencing of TCR transcripts Total RNA was
extracted using EUROZOL (Euroclone) from 106 cells for T cell clones
and from 4106 cells for PBMC. First-strand cDNA was synthesized
using oligo d(T) and Moloney murine leukemia virus reverse transcriptase
(Invitrogen, Paisley, UK) in 20 ml ¢nal volume. To verify the integrity of
each mRNA sample, an RT-PCR with primers speci¢c for the b-actin
gene was performed. The primers were as follows: b-actin forward 50 -
ACACTGTGCCCATCTACGAGGGG-30, b-actin reverse 50 -ATGATGGA
GTTGAAGGTAGTTTCGTGGAT-30. The actin PCR pro¢le was 2 min at
941C, 30 cycles at 941C for 30 s, 721C for 20 s, 721C for 30 s, followed by a
7 min extension. cDNA aliquots were PCR ampli¢ed in parallel with a
panel of 32 AV-speci¢c and 24 BV-speci¢c oligonucleotides in
conjunction with one AC-speci¢c (50 -GTTGCTCCAGGCCGCGGCAC
TGTT-30) and one BC-speci¢c (50 -TGCTGACCCCACTGTCGACCTC
CTTCCCATT-30) oligonucleotide. The AV-speci¢c primers were taken
from the literature (GeneveŁ e et al, 1992; Han et al, 1999).
The BV-speci¢c primers were as follows: BV1 50 -GCACAACAGTT
CCCTGACTTGCAC-30, BV2 50 -TCATCAACCATGCAAGCCTGAC
CT-30, BV3 50 -GTCTCTAGAGAGAAGAAGGAGCGC-30, BV4 50 -TTC
CCATCAGCCGCCCAAACCTAA-30, BV5 50 -ATACTTCAGTGAGACA
CAGAGAAA-30, BV6 50 -TCTCAGGTGTGATCCAAATTCGGG-30, BV7
50 -CACCTGAATGCCCCAACAGCTCTC-30, BV8 50 -ATTTACTTTAA
CAACAACGTTCCG-30, BV9 50 -TTCCCTGGAGCTTGGTGACTCT
GC-30, BV10 50 -CTCCAAAAACTCATCCTGTACCTT-30, BV11 50 -TC
AACAGTCTCCAGAATAAGGACG-30, BV12 50 -TGTCACCAGACTGG
GAACCACCAC-30, BV13 50 -CACTGCGGTGTACCCAGGATATGA-30,
BV14 50 -GTCTCTCGAAAAGAGAAGAGGAAT-30, BV15 50 -CAGGCA
CAGGCTAAATTCTCCCTG-30, BV16 50 -TGAAAGAGTCTAAACAGG
ATGAGT-30, BV17 50 -TCCTCTCACTGTGACATCGGCCCA-30, BV18
50 -GATGAGTCAGGAATGCCAAAGGAA-30, BV19 50 -TCAATGCCC
CAAGAACGCACCCTG-30, BV20 50 -ATCAGCTCTGAGGTGCCCCA
GAAT-30, BV21 50 -ATTCACAGTTGCCTAAGGATCGAT-30, BV22 50 -
GGGCAGAAAGTCGAGTTTCTGGTT-30, BV23 50 -TTTTATGAAAAG
ATGCAGAGCGAT-30, BV24 50 -AAGTCAAGTCAGGCCCCAAAGC
TG-30.
The TCRAV PCR pro¢le was 2 min at 941C, 30 cycles at 941C for 1
min, 601C for 30 s, 721C for 30 s, followed by a 7 min extension. The
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TCRBV PCR pro¢le was 2 min at 941C, 35 cycles at 941C for 30 s, 551C
for 20 s, 721C for 1min, followed by a 7 min extension. PCR ampli¢cation
products were puri¢ed using JetSorb gel extraction kit (Genomed, Bad
Oeynhausen, Germany) and directly sequenced with the BigDye
Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA)
using internal AC-speci¢c (50 -GTCACTGGATTTAGAGTC-30) and BC-
speci¢c (50 -TGCTTCTGATGGCTCAA-30) oligonucleotides according to
the manufacturer’s instructions. Sequences were run on an ABI 377 DNA
sequencer (Applied Biosystems). The TCR nomenclature proposed by
Arden et al (1995) was adopted.
Blotting and oligotyping The PCR samples were separated by 1.5%
agarose gel electrophoresis and alkali-blotted onto Hybond-Nþ
membrane (Amersham Pharmacia Biotech). Filters were prehybridized in
BLOTTO solution (6 sodium citrate/chloride bu¡er, 1% milk, 5 mM
ethylenediamine tetraacetic acid, 0.1% sodium dodecyl sulfate) at 371C for
3 h and hybridized overnight at 371C with the following, internal
oligonucleotides: PSAS34N 50 -TTACCGGGACTTTCTCTAAACG-30,
PSAS33N 50 -TCAGCGGGGGGACCACACC-30, PSAS38N 50 -TAGTTC
CGGTGGAGCGGG-30, PSAS43N 50 -GCAGTTACGATACGCTGGGC-
30, PSAS31N 50 -AGCCCGGGACTAGCGTACTAC-30, 4.7 N 50CCACCA
GCAGAGCCCCGGGAC-30.
RESULTS
Functional analysis of tetramer-guided ex vivo sorted cells
from one HLA-An0201 vitiligo patient reveals three groups
of Melan-A-speci¢c clones with variable avidity of antigen
recognition A blood sample was obtained after signed
informed consent from the vitiligo patient PSA in October
2000. Freshly isolated PBMC were stained with £uorescent
HLA-A2 tetramers complexed with the immunodominant
Melan-A peptide (A2/Melan-A tetramers) and anti-CD8
monoclonal antibody directly ex vivo, without any antigen-
speci¢c stimulation, and analyzed by £ow cytometry. The A2/
Melan-A tetramerþ T cells represented 0.16% of the CD8þ cells
at this time point and exhibited a mixed phenotype composed of
na|«ve (CD45RAþCD28þ, 57%), e¡ector (CD45RAþCD28^,
15%), and memory cells (CD45RA^CD45ROþ, 24%) (data not
shown). The CD8þ tetramerþ population was isolated by £ow
cytometry cell sorting and sorted cells were more than 98% pure
(not shown). The sorted population was immediately cloned by
limiting dilution, and 29 clones, all staining positive to the
tetramers (not shown), were functionally characterized. Avidity
of antigen recognition was assessed by titrating both Melan-A
A27L analog and Melan-A26^35 natural peptides in a functional
CTL assay on T2 target cells. Three groups of clones were
distinguishable according to their functional activity: group 1
clones that speci¢cally lyzed both Melan-A A27L and Melan-
A26^35 pulsed T2 cells; group 2 clones that recognized Melan-A
A27L peptide but failed to speci¢cally lyze Melan-A26^35 pulsed
T2 cells; and group 3 clones that failed to signi¢cantly recognize
the two Melan-A peptides (Table I and Fig 1a). Redirected lysis
experiments were performed to ascertain functionality of the
clones belonging to group 3. Only one clone (clone 14) was
found to be nonfunctional (not shown). TCR downregulation
upon peptide encounter was found to perfectly correlate with
the functional avidity of the clones (Fig 1b for some
representative cases), supporting the above classi¢cation.
Molecular characterization of the peripheral TCR repertoire
speci¢c for the Melan-A antigen To study the TCR-ab
repertoire displayed by the CD8þ A2/Melan-A tetramerþ T
cells, cDNA obtained from the 29 clones was subjected to RT-
PCR using a panel of 32 AV-speci¢c and 24 BV-speci¢c
oligonucleotides together with one AC-speci¢c and one BC-
speci¢c primer. Surprisingly, all clones analyzed (28 of 29; for
one clone the TCR-a rearrangement could not be determined)
expressed the same rearranged AV segment (Fig 2a and
Mantovani et al, 2002). In contrast, Melan-A-speci¢c CD8þ T
cells from this patient were found to rearrange many distinct BV
gene segments, though the preferential use of some V elements
was observed: ¢ve BV segments (BV2, BV7, BV9, BV13, and
BV14) accounted for 69% of clones analyzed (Fig 2a). We then
performed complementarity determining region 3 (CDR3)
analysis through direct sequencing of the ampli¢ed products
using an internal BC-speci¢c primer. Recurrent clonotypes were
never observed, indicating a largely polyclonal repertoire of
circulating Melan-A-speci¢c cells in this patient (Fig 2b). Clones
belonging to group 1 exhibited a certain degree of TCR-b
structural conservation as all but one (clone 43) used BJ segments
belonging to cluster 2.
Previously, T cell clones had been generated from this patient
(February 1999) by limiting dilution from a Melan-A-sensitized
cell line (Palermo et al, 2001). The relative avidity of all clones
analyzed turned out to be extremely high and to directly
correlate with their in vitro antimelanocytic activity (Palermo
et al, 2001). The molecular TCR composition of those clones was
here de¢ned and compared to the data obtained with the ex vivo
sorted cells. All clones rearranged the same AV segment (AV2) as
the sorted cells, and we found that the in vitro culture had selected
Table I. Avidity of A2/Melan-A tetramerþ clones from one vitiligo patient
Group 1 Group 2 Group 3
PSA clones A27La Melan-A26^35
b PSA clones A27L Melan-A26^35 PSA clones A27L Melan-A26^35
31 0.3 4.7 27 2.1 negc 6 neg neg
33 1.2 213 2 3130 neg 12 neg neg
21 2.1 2.1 48 4790 neg 26 neg neg
34 7.3 332 13 5000 neg 36 neg neg
43 43 559 28 45000 neg 41 neg neg
59 68 45000 49 45000 neg 45 neg neg
38 163 45000 8 45000 neg 50 neg neg
20 230 45000 29 45000 neg 53 neg neg
54 neg neg
55 neg neg
56 neg neg
60 neg neg
14 non-functionald
aNanomolar concentration of Melan-A A27L peptide required for 50% maximal lysis of pulsed T2 cells by the corresponding CTL clone.
bNanomolar concentration of Melan-A26^35 peptide required for 50% maximal lysis of pulsed T2 cells by the corresponding CTL clone.
cNo lysis.
dNon-functional in redirected lysis experiments.
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three clonotypes (Fig 3a). One clonotype appeared to be
overrepresented (¢ve of eight clones, represented by clone 4.7
hereafter). It showed the highest reactivity against HLA-matched
melanoma cell lines (Palermo et al, 2001) and, analogously to the
clones belonging to group 1, it possessed a high avidity of antigen
recognition for both Melan-A A27L and Melan-A26^35 peptides
(Fig 3b) and used a cluster 2 BJ segment (Fig 3a). TCR down-
regulation upon peptide encounter was again found to perfectly
correlate with the functional avidity of the clone (Fig 3c).
Interestingly, this clone contained an amino acid sequence (PGLA)
in its CDR3b that was either integrally or partially shared by
three ex vivo sorted cell clones belonging to group 1 (Fig 3d).
This suggests that this amino acid motif confers a high TCR
a⁄nity for the Melan-A antigen.
Melan-A-speci¢c clones from vitiligo possess skin homing
capability and antimelanocyte reactivity Four of the
highest avidity clones belonging to group 1 as well as clone 4.7
were assayed for their expression of CLA, which confers
homing to the skin, and for their ability to lyze normal
melanocytes, typically expressing low levels of the Melan-A
antigen. All ¢ve clones were found to be CLA positive, though
with di¡erent degrees of surface expression (Fig 4a). Im-
portantly, these clones were also found capable of speci¢cally lysing
normal HLA-matched melanocytes (Fig 4b): a signi¢cant lysis,
above 20%, was reached by four of the ¢ve clones at relatively
low E:T ratios.
Long-term peripheral persistence of high avidity Melan-A-
speci¢c clones In order to evaluate the longevity in peripheral
blood of the Melan-A-speci¢c clones belonging to group 1, RNA
was extracted from the patient’s PBMC collected over a 3 y
period. Persistence of the individual clones was assessed through
BV-speci¢c RT-PCR followed by oligotyping with clone-
speci¢c CDR3b probes. The sensitivity of this approach,
inherently very high, is limited by the relative number of
PBMC used for the experiment. The calculated lower detection
limit in our case is 1:15,000, meaning that, in order to be
Figure1. Ex vivo sorted A2/Melan-A tetramerþ T cells from an HLA-A2þ vitiligo patient can be classi¢ed into three functional groups.
Sorted A2/Melan-A tetramerþ CD8þ T cells were cloned by limiting dilution immediately after sorting and 29 independent clones were analyzed. (a)
Avidity of three representative tetramerþ vitiligo clones as measured in a standard 4 h chromium release assay against T2 cells pulsed with increasing
concentrations of either the natural Melan-A26^35 peptide (’) or the analog Melan-A A27L peptide (), at an E:T ratio of 5:1. Group 1 clones speci¢cally
lyzed both Melan-A A27L and Melan-A26^35 pulsed T2 cells; group 2 clones recognized Melan-A A27L peptide but failed to lyze Melan-A26^35 pulsed T2
cells; and group 3 clones failed to signi¢cantly recognize the two Melan-A peptides. At the same E:T ratio, lysis of emptyT2 cells was used as negative
control (m). Points are means of triplicates. Data shown represent one of three experiments with similar results. (b) Clones were tested in TCR down-
regulation experiments. T2 cells were pulsed with increasing concentrations of the natural (Melan-A26^35,’), the analog (Melan-A A27L, ), or an irrele-
vant (MAGE-3, m) peptide and added to e¡ector cells to give a ¢nal E:T ratio of 1:5. After 1.5^3 h at 371C, TCR internalization was measured by £ow
cytometry using an anti-TCR antibody. The ¢gure shows all group 1 clones and one representative case for each of the other two groups. Data shown
represent one of two experiments with similar results.
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detected, each clone must represent at least 1 cell in 15,000 CD8þ
cells. As shown in Fig 5, persistence of the di¡erent clones was
highly variable, ranging from less than 4 mo for clones 33 and
38 (these clones were isolated by tetramer sorting on October
2000 but they were not detectable among PBMC collected on
February 2001) up to more than 3 y for clones 31, 34, and 43.
Clone 4.7 displayed an intermediate, though not precisely
determinable, persistence, possibly shorter than 20 mo.
DISCUSSION
In this study, we demonstrate the presence of melanocyte-speci¢c
CD8þ Tcells in the peripheral blood of an HLA-An0201vitiligo
patient and describe their molecular and functional features. The
long-term persistence of some high avidity autoreactive CTL
clones is also demonstrated. Those autoreactive CTL exhibit in-
tact functional properties and antimelanocyte reactivity, exhibit a
high avidity of antigen recognition, and express the skin homing
receptor CLA. Overall, these ¢ndings strongly support an asso-
ciation between the presence of melanocyte-speci¢c CTL and vi-
tiligo, and directly point to their pathogenic role in this disease.
To our knowledge, this is the ¢rst time that lysis of normal cul-
tured melanocytes is demonstrated for antigen-speci¢c vitiligo T
lymphocytes.
Few studies have attempted to characterize theTCRusage of T
cells identi¢ed by tetramers in melanoma (Valmori et al, 2000;
Dietrich et al, 2001; Schrama et al, 2001; Mandruzzato et al, 2002),
and prior to this report no such studies have been performed in
vitiligo, with the only exception a partial characterization limited
to the a chain (Mantovani et al, 2002). Our results concerning
Melan-A-speci¢c CD8þ Tcells from vitiligo reveal a large reper-
toire of circulating Melan-A-speci¢c T lymphocytes, a feature
shared by all the Melan-A responses previously studied by the
use of tetramers in melanoma, yet a certain degree of TCR struc-
tural conservation. Although there is always a potential bias that
subpopulations of autoreactive T cells may display di¡erential
growth characteristics in vitro leading to the expansion of selected
T cell clones, the polyclonality of the population analyzed repre-
sents a good indication for absence of such a bias in our sample.
The dominant use of the same AV segment in this patient, which
Figure 2. Molecular characterization of Melan-A-speci¢c T cell
clones ex vivo isolated from the PBMC of an HLA-A2þ vitiligo
patient. (a) Sorted A2/Melan-A tetramerþ CD8þ T cells were cloned by
limiting dilution immediately after sorting and 29 independent clones
were analyzed for their AV and BV usage by RT-PCR. The percentages of
clones rearranging every speci¢c V segment are shown. The AV rearrange-
ment of one clone could not be determined. (b) CDR3b junctional amino
acid sequences of the 29 T cell clones are shown. One clone (#14) could
not be assigned to any of the groups as it turned out to be nonfunctional
(see Results). These sequence data are available from GenBank/EMBL/
DDBJ under accession nos. AY190086AY190091, AY190093AY190115.
Figure 3. Molecular characterization of Melan-A-speci¢c T cell
clones previously isolated from a Melan-A-sensitized T cell line
from the same HLA-A2þ vitiligo patient. PBMC had been isolated
from the vitiligo patient PSA in February 1999 and T cell clones were ob-
tained by limiting dilution from a T cell line obtained from these PBMC
upon three rounds of peptide-speci¢c stimulations. (a) AV and BV usage
was determined for eight clones by RT-PCR. CDR3b junctional amino
acid sequences are shown. These sequence data are available from
GenBank/EMBL/DDBJ under accession nos. AY190085, AY227209, and
AY229993. (b) Avidity of clone 4.7 as measured in a standard 4 h chromium
release assay against T2 cells pulsed with increasing concentrations of either
the natural Melan-A26^35 peptide (’) or the analog Melan-A A27L pep-
tide (), at an E:T ratio of 5:1. This cell clone was found to lyze with high
avidity both Melan-A A27L pulsed T2 cells (avidity 0.3) and Melan-A26^35
pulsed T2 cells (avidity 12.7). At the same E:T ratio, lysis of emptyT2 cells
was used as negative control (m). Points are means of triplicates. Shown is
one of three experiments with similar results. (c) Clone 4.7 was tested in
TCR downregulation experiments. T2 cells were pulsed with increasing
concentrations of the natural (Melan-A26^35, ’), the analog (Melan-A
A27L, ), or an irrelevant (MAGE-3, m) peptide and added to e¡ector cells
to give a ¢nal E:T ratio of 1:5. After 1.5 h at 371C,TCR internalization was
measured by £ow cytometry using an anti-TCR monoclonal antibody.
Shown is one of two experiments with similar results. (d) CDR3b junc-
tional amino acid sequences of the Melan-A-speci¢c clones sharing a con-
served amino acid consensus motif.
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we know to be a conserved feature of all Melan-A-speci¢c
populations we have studied so far (Mantovani et al, 2002), is
particularly striking and might re£ect a structural constraint
imposed on the TCR for engagement with Melan-A peptides
presented by HLA-A2. This, presumably low-a⁄nity, interaction
mediated by the a chain would be necessary for intrathymic
positive selection and peripheral homeostatic proliferation of all
Melan-A-reactive na|«ve T cells. On the other hand, the presence
of a conserved amino acid motif in the CDR3b of some high
avidity cells, together with the selective use of certain BJ and, to
a lesser extent, BV segments, might suggest an important role of
the b chain in ¢ne-tuningTCR a⁄nity of the speci¢c cells. From
this standpoint it is intriguing that a high avidity Melan-A-speci-
¢c clone, present in this patient at the ¢rst evaluation, had 20 mo
later been substituted by other clones with comparable avidity
and sharing manyTCR-b similarities.
At variance with theTcell clones we previously isolated from a
Melan-A-sensitized cell line from this vitiligo patient, which
homogeneously exhibited high avidity of Melan-A recognition
(Palermo et al, 2001), ex vivo isolated tetramerþ T cell clones dis-
played a large heterogeneity in terms of both avidity and ¢ne
speci¢city. Clones reacting with the natural Melan-A26^35 peptide
represented only a minority of the total population and were
among the ones displaying higher avidity of recognition of Mel-
an-A A27L analog pulsed cells. Surprisingly, a signi¢cant propor-
tion of ex vivo sorted tetramerþ T cell clones failed to recognize
the two Melan-A peptides. Possibly, these clones exhibited some
degree of speci¢city for Melan-A antigen, su⁄cient to bind A2/
Melan-A tetramers, but their functional avidity was too low to be
detected in a functional assay. Although we cannot formally de-
monstrate it, we believe that these clones represent essentially na-
|«ve cells that are speci¢c for some of the many Melan-A epitope
mimics described so far (Loftus et al, 1996; Rubio-Godoy et al,
2002) and that they do not participate in the antimelanocyte im-
mune response in this patient. This would explain the presence of
a conspicuous fraction of na|«ve A2/Melan-A tetramerþ cells in a
patient with a long-lasting disease. Our data are in perfect agree-
ment with those recently reported by Dutoit et al (2002) on na|«ve
A2/Melan-A-reactive populations from normal donors, where the
authors detected the same three functionally distinct groups of
tetramerþ clones, and possibly re£ect the fact that the tetramerþ
cells of our patient PSA contain a signi¢cant proportion of na|«ve
cells. These results also suggest that in vitro antigen stimulation is
the method of choice to select high avidity, self-speci¢c cells from
patients’ PBMC.
The patient we examined in this work had a clinically stable
disease during the entire follow-up period. Accordingly, the
Figure 4. Skin-homing capability and antimelanocyte activity of A2/Melan-A tetramerþ vitiligo clones. (a) Four clones belonging to group 1
and clone 4.7 were tested for their surface expression of CLA by £uorescence-activated cell sorter staining using a speci¢c monoclonal antibody. (b) The
same clones were tested in 5 h chromium release assays for their ability to lyze an HLA-A2þ normal melanocyte cell line (’) at di¡erent E:T ratios. Lyses
of an HLA-A2^ normal melanocyte cell line () were used as negative control. Points are means of duplicates.
Figure 5. Peripheral persistence of Melan-A-speci¢c clones. RNA
was extracted from PBMC collected over a 3 y period. Persistence of the
individual clones was assessed by a combination of RT-PCR and Southern
blotting. cDNA was PCR ampli¢ed (35 cycles) with BV-speci¢c primers
and the corresponding products were blotted and hybridized with clone-
speci¢c CDR3b probes. Lane þ , positive control, cDNA obtained from
the corresponding clones. A 1:10 dilution of the same product is loaded in
the following lane. Lane, negative control, no cDNA. As a control of
cDNA integrity, the ethidium bromide stained gel shows the actin RT-
PCR products (30 cycles) obtained from the di¡erent PBMC aliquots.
The arrow indicates the sorting date (October 2000).
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fraction of tetramerþ cells that had signs of antigen encounter in
vivo were predominantly of the memory phenotype, with only
few bona ¢de e¡ectors. Di¡erent Melan-A-speci¢c CD8þ clones
showing variable longevity were apparently detectable, however.
This could suggest that the repertoire of autoimmuneTcells con-
tinues to evolve even when the disease is apparently stable, pre-
sumably due to the persistence of su⁄cient amounts of the
sensitizing antigen. Alternatively, we might have failed to detect
all clones at each time point due to sensitivity limitations of the
technique we used. In this case, the autoimmune repertoire
would be more stable and maintained by a ¢xed pool of long-
lived memory cells.
A characteristic shared by several di¡erent models of autoim-
munity is the change in the repertoire that occurs during the
course of disease progression. Away by which antigen availabil-
ity can change the repertoire is through alterations in the avidity
of the T cells that recognize autoantigens. A number of studies
have found that, during the course of an immune response to for-
eign antigen, selection occurs in favor of T cells that have high
a⁄nity for antigen and that these high a⁄nity selected cells are
the ones that enter the memory pool (Busch and Pamer, 1999;
Rees et al, 1999; Savage et al, 1999; Amrani et al, 2000). It is possible
that this also occurs in an autoimmune response. Features of a⁄-
nity maturation are increasingly restricted TCR repertoires and
average increased avidity (McHeyzer-Williams and Davis, 1995;
Busch and Pamer, 1999). In this respect, the restricted range of
high avidities displayed by group 1 T cell clones, the preferential
use of speci¢c AV and BV segments, and the selection for con-
served CDR3 motifs might suggest that a⁄nity maturation oc-
curred in the Melan-A/MART-1-speci¢c T cell population
during vitiligo development.
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